A precedential ruling confirms that trade secret plaintiffs must identify their secrets with specificity or lose both discovery and their claims.
A precedential decision finds drug-releasing fiber claims anticipated by a single reference and the accused stent coating outside the claims.
A precedential ruling holds cancer treatment dosing claims invalid under Section 112(a), erasing a nine-figure jury award.
Narrowing claims to one industry did not move them outside the abstract idea category.
